thus the importance of understanding the MOA this could validate a lot of the claims that were rejected. So basically MOA not required for Pharma or FDA but potentially for a patent.
Side note, they didn’t agree that Bisantrene self rescues but rather it was just heart safe to begin with. Thus more work for Dr Jensen to firm up.
Also ARA-C previously released so prior art unless something more novel is identified. And more proof to expand to all anthracyclines and herceptin per the triangle report.
thus the importance of understanding the MOA this could validate...
-
- There are more pages in this discussion • 3,523 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |